Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma (RATiFY)

NCT05627115 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT05627115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05627115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma (RATiFY)
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2024
Completion date
October 1, 2028
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma